Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umut Demirci

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Cancers|October 16, 2024
Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group StudyEbru Karci, Ahmet Bilici, Buket Bayram, et al.
Frontiers in Pharmacology|January 5, 2026
Multilocus inherited neoplasia allele syndrome (MINAS) in a Turkish cohort: molecular insights and clinical relevance for precision oncologyTaha Bahsi, Serhat Seyhan, Kaan Helvaci, et al.
Breast Care (Basel, Switzerland)|October 11, 2016
Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology)Muhammet A Kaplan, Ulku Y Arslan, Abdurrahman Işıkdogan, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|July 17, 2015
Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction CancersMeltem Baykara, Mustafa Benekli, Ozgur Ekinci, et al.
Acta Oncologica (Stockholm, Sweden)|April 21, 2023
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH studyAhmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 24, 2026
The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancerIrem Bilgetekin, Umut Demirci, Hasan Cagri Yildirim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH TrialKevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, et al.
Current Medical Research and Opinion|May 29, 2024
Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry studyNuri Karadurmus, Muhammet Ali Kaplan, Mehmet Ali Nahit Sendur, et al.
Journal of Cancer Research and Therapeutics|December 17, 2021
Merkel cell carcinoma in Turkey: A multicentric studyFatih Yildiz, Umut Demirci, Ahmet Küçükarda, et al.
The New England Journal of Medicine|June 2, 2025
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast CancerMario Campone, Michelino De Laurentiis, Komal Jhaveri, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Cancers|October 16, 2024
Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group StudyEbru Karci, Ahmet Bilici, Buket Bayram, et al.
Frontiers in Pharmacology|January 5, 2026
Multilocus inherited neoplasia allele syndrome (MINAS) in a Turkish cohort: molecular insights and clinical relevance for precision oncologyTaha Bahsi, Serhat Seyhan, Kaan Helvaci, et al.
Breast Care (Basel, Switzerland)|October 11, 2016
Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology)Muhammet A Kaplan, Ulku Y Arslan, Abdurrahman Işıkdogan, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|July 17, 2015
Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction CancersMeltem Baykara, Mustafa Benekli, Ozgur Ekinci, et al.
Acta Oncologica (Stockholm, Sweden)|April 21, 2023
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH studyAhmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 24, 2026
The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancerIrem Bilgetekin, Umut Demirci, Hasan Cagri Yildirim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH TrialKevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, et al.
Current Medical Research and Opinion|May 29, 2024
Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry studyNuri Karadurmus, Muhammet Ali Kaplan, Mehmet Ali Nahit Sendur, et al.
Journal of Cancer Research and Therapeutics|December 17, 2021
Merkel cell carcinoma in Turkey: A multicentric studyFatih Yildiz, Umut Demirci, Ahmet Küçükarda, et al.
The New England Journal of Medicine|June 2, 2025
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast CancerMario Campone, Michelino De Laurentiis, Komal Jhaveri, et al.
Pageof 12